ArteraAI develops multimodal artificial intelligence (MMAI) biomarker tests that combine digital biopsy-image analysis and patient clinical data to provide predictive and prognostic results. Its flagship ArteraAI Prostate Test is designed to predict whether a patient will benefit from a particular therapy and to determine prognosis for localized prostate cancer. The MMAI algorithm has been validated using many Phase 3 randomized trials. The test is clinically available through a CLIA-certified laboratory in Jacksonville, Florida. The company says it will use new funding to support international expansion and commercial growth of the company and its test. ArteraAI is led by CEO Andre Esteva and focuses on personalizing cancer therapy through AI-enabled diagnostics. Artera builds multimodal artificial intelligence tests that provide prognostic risk stratification and predict therapeutic benefit for cancer patients. Its flagship product, the ArteraAI Prostate Test, is described as the first test to predict therapy benefit in localized prostate cancer. The company launched publicly with $90 million in funding from a syndicate of institutional and angel investors to support U.S. and international distribution of the prostate test. Artera plans to use the investment to develop additional tests to support therapy personalization in other cancers. The ArteraAI Prostate Test is clinically available as a laboratory-developed test through a CLIA-certified laboratory in Jacksonville, Florida and can be ordered online. The company reported positive data at ASCO GU 2023 showing validation of its prognostic biomarker across six phase III randomized trials.

Total raised

$110M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024